Biotech and Pharma Industry News | BioPharma Dive
WEB23andMe’s independent board directors resign. In a letter to CEO Anne Wojcicki, the directors said they’d resign “rather than have a protracted and distracting difference of view with you” about the company’s future. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
Pharma News | BioPharma Dive
WEB4 days ago · Novo sinks on obesity drug results; Sanofi reveals anticipated MS data. A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged. By BioPharma Dive staff •Sept. 20, 2024.
The biopharma industry outlook on 2024: Guarded optimism for a …
WEBPublished Jan. 16, 2024. Ned Pagliarulo Lead Editor. Brian Tucker / BioPharma Dive. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a ...
Bristol Myers pays $100M for a different kind of ADC
WEBNov 6, 2023 · Bristol Myers Squibb is acquiring an antibody-drug conjugate to treat bone and blood cancers from multinational biotechnology startup Orum Therapeutics, the companies announced Monday. Under the terms of the deal, Bristol Myers will pay Orum $100 million for the program and commit to paying as much as $80 million more if certain milestones are met.
Chasing Novo and Lilly: The obesity drugs that could challenge …
WEBApr 30, 2024 · One study can start a pharmaceutical revolution. Four years ago, a large clinical trial run by Novo Nordisk showed a drug called semaglutide helped people with obesity lose, on average, around 15% of their weight.The results far exceeded what prior studies of other treatments had suggested was possible pharmaceutically, sparking a rush to research that has quickly reshaped the obesity drug field.
Radiopharmaceuticals for cancer: Making radiation precise
WEBAug 15, 2023 · When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drug’s maker, Endocyte. The decision was also another step forward for a long-studied research field that appears to finally be coming of age. The medicine, Pluvicto, is known as a “radiopharmaceutical.”.
Investors put $400M into biotech licensing obesity drugs from China
WEBMay 16, 2024 · Four life science investors are pouring $400 million into a new biotechnology startup that’s licensed a portfolio of weight loss medicines from Chinese drugmaker Jiangsu Hengrui Pharmaceuticals, according to a disclosure posted on the Shanghai Stock Exchange Thursday. The newly created company, …
Biotech News - BioPharma Dive
WEB4 days ago · As part of a broad restructuring, the company plans to reduce research spending by 20% over the next few years and ax five programs in early development. It won’t cut jobs, however, a spokesperson told BioPharma Dive. By Ben Fidler • Sept. 12, 2024. The latest biotech news for biopharmaceutical professionals.
10 clinical trials to watch in the first half of 2024
WEBJan 2, 2024 · Moderna and Pfizer both reported promising results in early testing last fall and have moved on to late-stage studies. Moderna appears positioned to get to the finish line first. Results from its Phase 3 trial could be coming in the first half of this year, according to a federal database. — Delilah Alvarado.
Zepbound, Mounjaro back in supply as Lilly resolves shortage
WEBAug 5, 2024 · Lilly reports second quarter earnings on Thursday, when sales and supply of tirzepatide are likely to be the main focus of analyst questions. The company in April raised its financial forecasts for the year by $2 billion due to revenue growth for Zepbound and Mounjaro, which together brought in $2.3 billion between January and March.